These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23663372)

  • 41. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis.
    Rejdak K; Leary SM; Petzold A; Thompson AJ; Miller DH; Giovannoni G
    Mult Scler; 2010 Sep; 16(9):1066-72. PubMed ID: 20639271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
    Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH;
    Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
    Inglese M; van Waesberghe JH; Rovaris M; Beckmann K; Barkhof F; Hahn D; Kappos L; Miller DH; Polman C; Pozzilli C; Thompson AJ; Yousry TA; Wagner K; Comi G; Filippi M
    Neurology; 2003 Mar; 60(5):853-60. PubMed ID: 12629246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of interferon-β1α therapy on multiple sclerosis based on gadolinium-enhancing or active T2 magnetic resonance imaging outcomes: a meta-analysis.
    Lu Y; Zhao J; Zhan Q
    Neurol Res; 2016 Oct; 38(10):909-15. PubMed ID: 27553873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary progressive multiple sclerosis: a shared therapeutic decision.
    Cantisani TA; Celani MG; Hankey GJ; Sandercock PA
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):365. PubMed ID: 23223334
    [No Abstract]   [Full Text] [Related]  

  • 47. Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
    Gurevich M; Miron G; Falb RZ; Magalashvili D; Dolev M; Stern Y; Achiron A
    BMC Neurol; 2015 Nov; 15():240. PubMed ID: 26589141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?
    Bonenfant J; Bajeux E; Deburghgraeve V; Le Page E; Edan G; Kerbrat A
    Eur J Neurol; 2017 Feb; 24(2):237-244. PubMed ID: 27753181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of primary progressive multiple sclerosis.
    Kantarci O
    Semin Neurol; 2013 Feb; 33(1):74-8. PubMed ID: 23709215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon-beta1a for the treatment of multiple sclerosis.
    Clerico M; Contessa G; Durelli L
    Expert Opin Biol Ther; 2007 Apr; 7(4):535-42. PubMed ID: 17373904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does interferon beta help in secondary progressive MS?
    Cohen JA; Antel JP
    Neurology; 2004 Nov; 63(10):1768-9. PubMed ID: 15557486
    [No Abstract]   [Full Text] [Related]  

  • 52. [Disease-modifying treatment of secondary progressive multiple sclerosis].
    Hoffmann O; Gold R
    Nervenarzt; 2021 Oct; 92(10):1052-1060. PubMed ID: 33656569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary progressive multiple sclerosis : current and future treatment options.
    Leary SM; Thompson AJ
    CNS Drugs; 2005; 19(5):369-76. PubMed ID: 15907149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.
    Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G
    Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Autoimmune functional disorders of the thyroid during interferon-beta-1b treatment in patients with multiple sclerosis. Case report and literature review].
    Lange-Asschenfeldt C; Boor S; Kahaly GJ; Thömke F
    Nervenarzt; 2004 Jun; 75(6):589-94. PubMed ID: 15257382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MRI and assessment of treatment in multiple sclerosis.
    Miller DH; Thompson AJ; Kappos L
    Brain; 2001 May; 124(Pt 5):1052-3. PubMed ID: 11335707
    [No Abstract]   [Full Text] [Related]  

  • 57. [A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3].
    Kotov SV; Kudlay DA; Lizhdvoy VY; Stashuk GA; Magomedova SB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):107-115. PubMed ID: 31156249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of London trial of intramuscular interferon-beta Ia in primary-progressive multiple sclerosis.
    Miller DH; Leary SM; Thompson AJ
    Mult Scler; 2004 Jun; 10 Suppl 1():S56-7. PubMed ID: 15218810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis.
    Patti F; Cataldi ML; Nicoletti F; Reggio E; Nicoletti A; Reggio A
    J Neurol Neurosurg Psychiatry; 2001 Sep; 71(3):404-7. PubMed ID: 11511721
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
    Rieckmann P; Toyka KV; Bassetti C; Beer K; Beer S; Buettner U; Chofflon M; Götschi-Fuchs M; Hess K; Kappos L; Kesselring J; Goebels N; Ludin HP; Mattle H; Schluep M; Vaney C; Baumhackl U; Berger T; Deisenhammer F; Fazekas F; Freimüller M; Kollegger H; Kristoferitsch W; Lassmann H; Markut H; Strasser-Fuchs S; Vass K; Altenkirch H; Bamborschke S; Baum K; Benecke R; Brück W; Dommasch D; Elias WG; Gass A; Gehlen W; Haas J; Haferkamp G; Hanefeld F; Hartung HP; Heesen C; Heidenreich F; Heitmann R; Hemmer B; Hense T; Hohlfeld R; Janzen RW; Japp G; Jung S; Jügelt E; Koehler J; Kölmel W; König N; Lowitzsch K; Manegold U; Melms A; Mertin J; Oschmann P; Petereit HF; Pette M; Pöhlau D; Pohl D; Poser S; Sailer M; Schmidt S; Schock G; Schulz M; Schwarz S; Seidel D; Sommer N; Stangel M; Stark E; Steinbrecher A; Tumani H; Voltz R; Weber F; Weinrich W; Weissert R; Wiendl H; Wiethölter H; Wildemann U; Zettl UK; Zipp F; Zschenderlein R; Izquierdo G; Kirjazovas A; Packauskas L; Miller D; Koncan Vracko B; Millers A; Orologas A; Panellus M; Sindic CJ; Bratic M; Svraka A; Vella NR; Stelmasiak Z; Selmaj K; Bartosik-Psujik H; Mitosek-Szewczyk K; Belniak E; Mochecka A; Bayas A; Chan A; Flachenecker P; Gold R; Kallmann B; Leussink V; Mäurer M; Ruprecht K; Stoll G; Weilbach FX;
    J Neurol; 2004 Nov; 251(11):1329-39. PubMed ID: 15592728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.